A major goal of the DF/HCC GI SPORE is to identify and support projects that test clinically meaningful hypotheses and approaches aimed at reducing the incidence and mortality rates of GI cancers. To these ends, a flourishing Developmental Research Program (DRP) supports short-range studies to establish the results needed to facilitate well-validated, hypothesis-driven translational projects. The DRP's mission is to foster new endeavors in GI cancer research, enable promising new individual and collaborative efforts, promote novel technologies that enhance the community's research potential, and advance individual projects from pilot to sustainable status. An important aspect of this mission is to identify and stimulate interest in GI cancer research among established and junior investigators whose current focus may be different, but whose ideas, expertise, and preliminary data have the potential for fresh and significant impact on GI cancers. In addition to pilot funds and access to Core resources, projects and investigators benefit greatly from integration and collaboration with a thriving community of GI SPORE investigators. The DRP is led a highly qualified and invested committee that represents a full range of laboratory, clinical, and population sciences across the DF/HCC member institutions. This committee actively identifies the best talent, selects awardees through a fair and transparent process, and participates in ongoing review of pilot projects and programmatic goals. In the prior funding cycle, DRP support for 19 innovative, diverse, and specifically translational projects enabled novel discoveries, substantial contributions to the literature, and more than 20 federal and foundation grants to sustain and advance GI cancer research. The DRP incorporates the depth and flexibility necessary to maintain innovation in GI SPORE activities; notably, 3 of the 4 main projects in this renewal application grew from original DRP support. The DRP will continue to support novel research in GI cancer, with the following specific aims: 1) Solicit pilot projects in translational GI cancer research that demonstrate significant potential for reducing the prevalence, suffering, and death from the full spectrum of GI cancers; 2) Foster collaborative efforts among SPORE and other investigators to enable the development of innovative ideas and laboratory and treatment approaches; 3) Monitor the progress of developmental projects and provide investigators with critical, timely feedback; 4) Encourage and assist investigators with promising preliminary data arising from DRP support to compete for peer- reviewed extramural funding; and 5) When necessary and promising, promote the most meritorious DRP projects to full SPORE research projects.

Public Health Relevance

The Developmental Research Program mission is to foster new endeavors in GI cancer research, enable promising new individual and collaborative efforts, promote novel technologies that enhance the community's research potential, and advance individual projects from pilot to sustainable status. This committee actively identifies the best talent, selects awardees through a fair and transparent process, and participates in ongoing review of pilot projects and programmatic goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-12
Application #
10005208
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-04-01
Project End
2024-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Qian, Zhi Rong; Rubinson, Douglas A; Nowak, Jonathan A et al. (2018) Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol 4:e173420
Nevo, Daniel; Nishihara, Reiko; Ogino, Shuji et al. (2018) The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure. Lifetime Data Anal 24:425-442
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Aguirre, Andrew J; Nowak, Jonathan A; Camarda, Nicholas D et al. (2018) Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8:1096-1111
Hill, Margaret A; Alexander, William B; Guo, Bing et al. (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78:4445-4451
He, Xiaosheng; Wu, Kana; Ogino, Shuji et al. (2018) Association Between Risk Factors for Colorectal Cancer and Risk of Serrated Polyps and Conventional Adenomas. Gastroenterology 155:355-373.e18
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Hu, Yang; Ding, Ming; Yuan, Chen et al. (2018) Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. Gastroenterology 154:916-926.e9

Showing the most recent 10 out of 590 publications